AI Stock Analysis - AbbVie (ABBV)
Analysis generated November 25, 2025.
AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company that engages in the research, development, manufacturing, and sale of pharmaceuticals. The company was separated from Abbott Laboratories in 2013 and has since grown into a major player in the industry. AbbVie focuses on various therapeutic areas such as immunology, oncology, neuroscience, virology, and eye care. Some of its well-known products include Humira, Imbruvica, and Venclexta.
Stock Alerts - AbbVie (ABBV)
 |
AbbVie | March 7 Insider Alert: Purdue David Ryan is selling shares |
|
AbbVie | March 4 Insider Alert: Siatis Perry C is selling shares |
|
AbbVie | February 4 Price is down by -6.4% in the last 24h. |
|
AbbVie | January 16 Julie Johnson (member of U.S. congress) is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for AbbVie
About AbbVie
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
| Price | $221.45 |
| Target Price | Sign up |
| Volume | 3,991,892 |
| Market Cap | $388B |
| Year Range | $182.05 - $240.68 |
| Dividend Yield | 2.95% |
| PE Ratio | 92.69 |
| Analyst Rating | 71% buy |
| Industry | Drug Manufacturers |
In the news
Is AbbVie Inc. (ABBV) A Good Stock to Buy Now?March 15 - Yahoo Entertainment |
|
Viokace (AbbVie) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FMarch 13 - GlobeNewswire |
|
Survanta (AbbVie) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FMarch 13 - GlobeNewswire |
|
AbbVie Reports Promising Results from Phase 1 Study of ABBV-295March 11 - Yahoo Entertainment |
|
Elahere (AbbVie: mirvetuximab soravtansine-gynx) Market Research Report 2026: Epidemiology, Competitive Landscape, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035FMarch 10 - GlobeNewswire |
|
AbbVie Inc. (ABBV) Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI Subcutaneous Induction in Patients with Crohn’s DiseaseMarch 9 - Yahoo Entertainment |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 16.6B | 2.66B | 14B | 1.82B | 16B | 2.710 |
| Q3 '25 | 15.8B | 5.3B | 10.5B | 186M | 3.52B | 1.860 |
| Q2 '25 | 15.4B | 4.35B | 11.1B | 938M | 4.34B | 2.970 |
| Q1 '25 | 13.3B | 4B | 9.34B | 1.29B | 4.4B | 2.460 |
| Q4 '24 | 15.1B | 4.4B | 10.7B | -22M | 535M | 2.160 |
Insider Transactions View All
| Purdue David Ryan filed to sell 2,654 shares at $233.6. March 6 '26 |
| Siatis Perry C filed to sell 4,619 shares at $235.3. March 3 '26 |
| Siatis Perry C filed to sell 17,510 shares at $233.5. March 3 '26 |
| Siatis Perry C filed to sell 7,219 shares at $234.7. March 3 '26 |
| Siatis Perry C filed to sell 38,137 shares at $230. February 27 '26 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Julie Johnson |
Jan 16, 26 | Sell | $1K - $15K |
| Julia Letlow |
Jan 14, 26 | Buy | $1K - $15K |
| Julia Letlow |
Jan 14, 26 | Sell | $1K - $15K |
Read more about AbbVie (ABBV) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - AbbVie
The Market Cap of AbbVie is $388B.
As of today, AbbVie's PE (Price to Earnings) ratio is 92.69.
Currently, the price of one share of AbbVie stock is $221.45.
The ABBV stock price chart above provides a comprehensive visual representation of AbbVie's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling AbbVie shares. Our platform offers an up-to-date ABBV stock price chart, along with technical data analysis and alternative data insights.
Yes, AbbVie (ABBV) offers dividends to its shareholders, with a dividend yield of 2.95%. This dividend yield represents AbbVie's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering AbbVie in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of AbbVie are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and TherapeuticsMD.
